Novel potent benzimidazole-based microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors derived from BRP-201 that also inhibit leukotriene C4 synthase

Eur J Med Chem. 2022 Mar 5:231:114167. doi: 10.1016/j.ejmech.2022.114167. Epub 2022 Feb 1.

Abstract

Microsomal prostaglandin E2 synthase-1 (mPGES-1) is recognized as a promising therapeutic target for next-generation anti-inflammatory drugs to treat inflammatory diseases. In this study, we report the identification of new, potent and selective inhibitors of human mPGES-1 such as compounds 10, 31 and 49 with IC50 of 0.03-0.09 μM in a cell-free assay of PGE2 production. Compound 10 and 49 also inhibited leukotriene C4 synthase (LTC4S) at sub-μM concentrations (IC50 = 0.7 and 0.4 μM, respectively), affording compounds dually targeting inflammatory PGE2 and cysteinyl leukotriene (cys-LT) biosynthesis. However, compound 31 showed substantial selectivity towards mPGES-1 (IC50 = 0.03 μM) with a decreased inhibitory activity on LTC4S (IC50 = 2.8 μM), and also on other related targets such as FLAP and 5-LO. These oxadiazole thione-benzimidazole derivatives warrant further exploration of new and alternative analogs that may lead to the identification of novel derivatives with potent anti-inflammatory properties.

Keywords: Benzimidazole; Benzyloxy; Leukotriene; Oxadiazolethione; PGE(2); mPGES-1.

MeSH terms

  • Anti-Inflammatory Agents / pharmacology
  • Benzimidazoles / pharmacology
  • Dinoprostone
  • Humans
  • Leukotriene C4*
  • Microsomes*
  • Prostaglandin-E Synthases

Substances

  • Anti-Inflammatory Agents
  • Benzimidazoles
  • Leukotriene C4
  • Prostaglandin-E Synthases
  • Dinoprostone